Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

1.0K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cryomilling of freeze dried low-Tg sugar glasses: A versatile method to prepare inhalable dry powder formulations.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Freeze-Drying in Sucrose Followed by Cryomilling Enables the Formulation of sa-mRNA-LNP Powders for Inhalation.

Pharmaceutics·2026
Same author

The environmental burden of inhalation.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2024
Same author

Plastic Venture Builder (PVB): An empirically derived assessment tool to support plastic waste management ventures in low- and middle-income countries.

Waste management & research : the journal of the International Solid Wastes and Public Cleansing Association, ISWA·2023
Same author

Effects of ileocolonic delivered vitamin B<sub>2</sub>, B<sub>3</sub> and C (ColoVit) or the Groningen anti-inflammatory diet on disease course and microbiome of patients with Crohn's disease (VITA-GrAID study): a protocol for a randomised and partially blinded trial.

BMJ open·2023
Same author

RANKL confers protection against cell death in precision-cut lung slices.

Frontiers in physiology·2022

Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.6K

Can Patients with Parkinson's Disease Use Dry Powder Inhalers during Off Periods?

M Luinstra1, A W F Rutgers2, H Dijkstra3

  • 1Department of Clinical Pharmacy, Martini Hospital, Groningen, The Netherlands; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.

Plos One
|July 15, 2015
PubMed
Summary

Parkinson's disease patients can effectively use dry powder inhalers (DPIs) during off periods for rapid levodopa delivery. This study confirms their ability to operate DPIs, supporting inhaled levodopa as a rescue treatment option.

More Related Videos

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.1K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K

Related Experiment Videos

Last Updated: Apr 7, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.6K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.1K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K

Area of Science:

  • Pulmonary Drug Delivery
  • Neurology
  • Biomedical Engineering

Background:

  • Oral levodopa is standard for Parkinson's disease (PD) but has delayed effects during off periods.
  • Pulmonary administration offers rapid onset for rescue treatment.
  • Assessing PD patients' ability to use dry powder inhalers (DPIs) during off periods is crucial.

Purpose of the Study:

  • To evaluate the usability of DPIs by Parkinson's disease patients during off periods.
  • To determine if PD patients can generate sufficient inspiratory flow rates for DPI operation.
  • To assess breath-holding capacity post-inhalation in PD patients.

Main Methods:

  • Utilized an instrumented test inhaler with varying resistances.
  • Recorded flow curves and calculated inhalation parameters.
  • Assessed pressure drops, inhaled volumes, inhalation times, and breath-holding duration.

Main Results:

  • All 13 PD patients generated adequate pressure drops (>2 kPa) with the highest resistance.
  • 10 out of 13 patients achieved ≥4 kPa, indicating sufficient inspiratory effort.
  • Inhaled volumes ranged from 1.2 L to 3.5 L; breath-holding capacity was generally sufficient (≥5 seconds for 12/13 patients).

Conclusions:

  • Parkinson's disease patients can operate DPIs effectively during off periods.
  • Inhaled levodopa via DPI is a viable strategy for rapid rescue treatment in PD.
  • Study data supports the development of levodopa DPIs for Parkinson's disease management.